person · Reporting owner

Pace Megan E

Disclosed activity across 1 company

Tapewire entity: 16474
SEC CIK: 0001554979

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	SVP, Corp. Communications	November 17, 2014	November 19, 2014

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

VERTEX PHARMACEUTICALS INC / MA

Report date November 17, 2014 · Filed November 19, 2014

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	43,350	Reported balance After 2014-11-17 transaction · row 1 1 source row Row 1 · 2014-11-17 · Sale · Disposed 33 · Balance 43,350 F1: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 08, 2013 Filed Jul 10, 2013 20:44 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	3,500	$37.86	$132,510.00	Disclosure SEC source: 0001209191-13-036102 · doc4.xml · nonDerivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 08, 2013 Filed Jul 10, 2013 20:44 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	22,500	$37.29	$839,025.00	Disclosure SEC source: 0001209191-13-036102 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 05, 2013 Filed Feb 7, 2013 22:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantEmployee Stock Option (right to buy) · Derivative	45,750	$0.00 Strike: $45.11	$0.00	Disclosure SEC source: 0001209191-13-007129 · doc4.xml · derivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document
February 05, 2013 Filed Feb 7, 2013 22:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	10,166	$0.01	$101.66	Disclosure SEC source: 0001209191-13-007129 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,915 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document
July 25, 2012 Filed Jul 26, 2012 21:02 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantEmployee Stock Option (right to buy) · Derivative	30,500	$0.00 Strike: $48.74	$0.00	Disclosure SEC source: 0001209191-12-039172 · doc4.xml · derivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2022-07-24 F1 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 10/25/2012. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.